Tempus AI Teams Up With Renalytix to Boost Adoption of Prognostic Blood Test for Kidney Disease

MT Newswires Live09-15

Tempus AI (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.

Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.

The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.

Tempus AI shares were up nearly 2% in recent premarket activity.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2567149401?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2025-09-15 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567149401","market":"sg","top_or_hot":-1,"title":"Tempus AI Teams Up With Renalytix to Boost Adoption of Prognostic Blood Test for Kidney Disease","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.</p><p>Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.</p><p>The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.</p><p>Tempus AI shares were up nearly 2% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Teams Up With Renalytix to Boost Adoption of Prognostic Blood Test for Kidney Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Teams Up With Renalytix to Boost Adoption of Prognostic Blood Test for Kidney Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-15 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.</p><p>Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.</p><p>The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.</p><p>Tempus AI shares were up nearly 2% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM.AU","symbol_name":"TEMPEST MINERALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2567149401","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567149401","pubTimestamp":1757940745,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tempus AI  has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.Tempus AI shares were up nearly 2% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM.AU":"TEMPEST MINERALS LTD","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK7095":"多种金属与采矿","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TEM":"Tempus AI","BK4613":"AI应用软件","BK4611":"AI医疗","BK4121":"生命科学工具和服务"},"translate_title":"Tempus AI与Renalytix合作推动肾脏疾病预后血液检测的采用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1,"TEM.AU":1},"content_text":"Tempus AI (TEM) has formed a partnership with Renalytix to boost adoption of the kidneyintelX.dkd prognostic blood test for eligible patients who have type 2 diabetes with chronic kidney disease, Renalytix said Monday.Renalytix said its kidneyintelX.dkd will be the first chronic kidney disease test in Tempus' portfolio, designed for use in risk prediction for progressive kidney function decline in type 2 diabetes patients with chronic kidney disease stages 1-3b.The tests will be processed at a Renalytix laboratory and the tests' insights will be used for making changes in patient management, potentially helping healthcare providers improve key metrics in diabetes and kidney care and mitigate kidney function decline, the company said.Tempus AI shares were up nearly 2% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2567149401","isCrawlerRequest":true}